Stuttgart - Delayed Quote EUR

Regeneron Pharmaceuticals Inc (RGO.SG)

Compare
653.00
-18.60
(-2.77%)
At close: 9:58:51 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
14,202,000
14,202,000
13,117,200
12,172,900
16,071,700
Cost of Revenue
1,970,500
1,970,500
1,815,800
1,560,400
2,437,500
Gross Profit
12,231,500
12,231,500
11,301,400
10,612,500
13,634,200
Operating Expense
8,139,800
8,139,800
7,068,200
5,618,500
4,639,400
Operating Income
4,091,700
4,091,700
4,233,200
4,994,000
8,994,800
Net Non Operating Interest Income Expense
656,200
656,200
422,900
100,700
-11,500
Other Income Expense
32,000
32,000
-456,800
-235,900
342,500
Pretax Income
4,779,900
4,779,900
4,199,300
4,858,800
9,325,800
Tax Provision
367,300
367,300
245,700
520,400
1,250,500
Net Income Common Stockholders
4,412,600
4,412,600
3,953,600
4,338,400
8,075,300
Diluted NI Available to Com Stockholders
4,412,600
4,412,600
3,953,600
4,338,400
8,075,300
Basic EPS
43.25
40.90
37.05
40.51
76.40
Diluted EPS
40.43
38.34
34.77
38.22
71.97
Basic Average Shares
107,600
107,900
106,700
107,100
105,700
Diluted Average Shares
115,125
115,100
113,700
113,500
112,200
Total Operating Income as Reported
3,990,700
3,990,700
4,047,100
4,738,900
8,946,800
Total Expenses
10,110,300
10,110,300
8,884,000
7,178,900
7,076,900
Net Income from Continuing & Discontinued Operation
4,412,600
4,412,600
3,953,600
4,338,400
8,075,300
Normalized Income
4,397,647.40
4,397,647.40
4,364,628.80
4,556,917.10
7,782,159
Interest Income
711,400
711,400
495,900
160,100
45,800
Interest Expense
55,200
55,200
73,000
59,400
57,300
Net Interest Income
656,200
656,200
422,900
100,700
-11,500
EBIT
4,835,100
4,835,100
4,272,300
4,918,200
9,383,100
EBITDA
5,318,000
5,318,000
4,693,300
5,259,600
9,669,300
Reconciled Cost of Revenue
1,970,500
1,970,500
1,815,800
1,560,400
2,437,500
Reconciled Depreciation
482,900
482,900
421,000
341,400
286,200
Net Income from Continuing Operation Net Minority Interest
4,412,600
4,412,600
3,953,600
4,338,400
8,075,300
Total Unusual Items Excluding Goodwill
16,200
16,200
-436,800
-244,700
338,500
Total Unusual Items
16,200
16,200
-436,800
-244,700
338,500
Normalized EBITDA
5,301,800
5,301,800
5,130,100
5,504,300
9,330,800
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,247.40
1,247.40
-25,771.20
-26,182.90
45,359
12/31/2021 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

5VA.F Vaxcyte, Inc.
69.50
-1.42%
 
RGTPQ RegenETP, Inc.
0.1500
0.00%
 
NB11.F Vaxart, Inc.
0.4818
-1.79%
 
0RQE.IL Idorsia Ltd
1.2420
-8.88%
 
RGRX RegeneRx Biopharmaceuticals, Inc.
0.0014
0.00%
 
ENTO Entero Therapeutics, Inc.
0.6100
+23.31%
 
TYRA Tyra Biosciences, Inc.
11.21
-4.27%
 
DBVT DBV Technologies S.A.
3.9600
-7.48%
 
NVCT Nuvectis Pharma, Inc.
6.14
-8.22%
 
ZVSA ZyVersa Therapeutics, Inc.
1.0500
-7.08%